IL6 and rheumatoid arthritis: Antibodies that block either IL-6 or the IL-6R are in clinical use to treat inflammatory diseases like rheumatoid arthritis [7], and designer proteins like Olamkicept that target specifically IL-6 trans-signaling are currently investigated in clinical studies [26].